Common Pain Relievers Linked to Elevated Blood Pressure in Men

Men who regularly take commonly available and widely used pain relievers may have an increased risk of high blood pressure of 48% compared with those who do not use these medications. Two large studies have recently suggested that analgesics may be associated with an increased risk of hypertension high blood pressure in women. However, the association has not been extensively studied in men.

John P. Forman, MSc, MD, of Brigham and Women’s Hospital and Harvard Medical School, Boston, and colleagues followed a total of 16,031 male health professionals (average age 64.6 years) who did not have a history of high blood pressure. The men were asked in 2000 and again in 2002 about whether and how often they used three types of pain relievers: acetaminophen, NSAIDs and aspirin. They were also asked to report if their physician had diagnosed them with hypertension.

Over four years of follow-up, 1,968 men developed hypertension. Compared with men who did not take analgesics, those who took acetaminophen six or seven days a week had a 34% higher risk of hypertension. Those who took NSAIDs six or seven days a week had a 38% higher risk and those who took aspirin six or seven days a week had a 26% higher risk.

The researchers also looked at the total number of pain-relieving pills men took each week, regardless of type. Compared with men who took no pills, those who took 15 or more pills each week had a 48% higher risk of hypertension.

All three types of analgesics may inhibit the effects of chemicals that relax the blood vessels, decreasing blood pressure, the authors suggest. Acetaminophen also may impair cell functioning through oxidative stress or reduce the proper functioning of blood vessel lining.

"These data add further support to the hypothesis that non-narcotic analgesics independently elevate the risk of hypertension," the authors write. "Given their common consumption and the high prevalence of hypertension, our results may have substantial public health implications and suggest that these agents be used with greater caution.

 Archives of Internal Medicine, Feb. 2007

===============================

FACT:
Diabetes Drug Saxagliptin Seen on Track for FDA: AstraZeneca and Bristol Myers Squibb have reiterated plans to seek FDA approval of their new type 2 diabetes drug, Saxagliptin, early next year, even though a similar Novartis drug has been delayed because of safety concerns. Saxagliptin, Galvus and Merck & Co.’s Januvia belong to a new class of drugs, so- called DPP-4 inhibitors, which increase and prolong the action of natural hormones in the body called incretins. While Januvia was approved in late 2006 and is already on the market, Novartis said last week that the Food and Drug Administration wants more data on Galvus, and observers believe the pill may be delayed for more than a year.  The FDA delay is believed a result of agency concern that a biproduct of Galvus may build up in patients with kidney problems and lead to skin lesions, which were seen in tests with laboratory animals. Saxagliptin also is associated with these skin lesions. Nevertheless, AstraZeneca Chief Executive Officer David Brennan told Bloomberg News that the U.K. drugmaker hasn’t "seen anything that would suggest to us that we have a particular issue. 

===============================

Dr. Bernstein will be doing another live teleconference on Tuesday March 27 at 7:00 P.M. CST 8:00 P.M. EST. If you would like to ask a question or just register for the free teleconference call, just go to https://www.diabetes911.net/askdrb/index.php and register. There were over 600 people on the last call. More info at https://www.diabetes911.net/askdrb/index.php